ALC

1.56%

6.5¢ alcidion group limited

to say it short, ALC = lame duck. Imo. Obviously market believes...

First 464 Last

Share
Profile

Follow
ravanelli77

1,082 Posts.

85

05/02/19

04:33

Post #: 37329218
Share

Originally posted by ZMan: ↑

Re: From the last quarterly report, the company said it has secured $14.8 millions contracted revenue for the first half year FY19,
This is an incorrect statement and understanding of the statement made in the quarterly report.

The actual statement was: "At the end of Q2 the contracted revenue which will be recognised in FY19 had increased to $14.8 million (up from $11.1 million at the end of Q1)."

This is effectively giving guidance for full year FY19 revenue to be recognised in the accounts of $14.8 mil. By stating that this is the "contracted revenue" shows that they are only relying upon signed contracts, not relying upon expected future sales or contracts.
Thus the guidance is very conservative and likely to grow during the year.

With a full year revenue of $14.8 mil, an estimate of the first 8 months of FY19 revenue would be $14.8/12*8 = $9.87 mil
Fy18 revenue was $4.2 mil, so 4 months worth is $1.4m

This gives a total of $11.3 mil, still well short of the $15 mil hurdle.

Expand

to say it short, ALC = lame duck. Imo. Obviously market believes that ALC plays a very tiny inexistent role in the future. Once I read (from my memory)that they wanted to enter US market in early 2018. embarrassing. think we are far far away to think at a glolal expansion. IMO

Last edited by ravanelli77: 05/02/19

ALC Price at posting: 4.1¢ Sentiment: Sell Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

MIN

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

WC8

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

NTI

Neurotech bounces back from FDA rejection with new NTI164 baseline study

ACW

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

There are more pages in this discussion • 160 more messages in this thread...

First 464 Last

Add ALC (ASX) to my watchlist

(20min delay)
Last 6.5¢		Change 0.001(1.56%)		Mkt cap ! $72.51M

Open	High	Low	Value	Volume
6.5¢	6.5¢	6.5¢	$1.523K	23.43K

Buyers (Bids)

No.	Vol.	Price($)
2	44679	6.3¢

Sellers (Offers)

Price($)	Vol.	No.
6.6¢	42258	1

View Market Depth

No.	Vol.	Price($)
1	256518	0.065
2	539747	0.064
1	200	0.063
1	10000	0.062
2	149000	0.061

Price($)	Vol.	No.
0.066	128118	1
0.068	232449	1
0.069	50000	1
0.070	160606	2
0.071	20177	1

Last trade - 10.36am 25/11/2024 (20 minute delay)

ALC (ASX) Chart

to say it short, ALC = lame duck. Imo. Obviously market believes...

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

Neurotech bounces back from FDA rejection with new NTI164 baseline study

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

to say it short, ALC = lame duck. Imo. Obviously market believes...

Top Stories

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

Neurotech bounces back from FDA rejection with new NTI164 baseline study

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News